Summary
Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
- The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
- The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB2 Bio Ltd.
Akari Therapeutics, Plc
Allergan Plc
Circadian Technologies Limited
Delenex Therapeutics AG
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
HanAll Biopharma Co., Ltd.
Herantis Pharma Plc
Huons Co., Ltd.
InSite Vision Incorporated
Kala Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Kukje Pharmaceutical Industry Co., Ltd.
Laboratorios Sophia S.A. de C.V.
Lee's Pharmaceutical Holdings Limited
Lipicard Technologies Limited
Merck & Co., Inc.
Mimetogen Pharmaceuticals Inc.
Mitotech S.A.
Nanomerics Ltd
Neuroptis Biotech
Novaliq GmbH
Ocular Therapeutix, Inc.
Oculis ehf
OncoNOx ApS
Otsuka Holdings Co., Ltd.
Parion Sciences, Inc.
PharmaReaserch Products Co., Ltd.
RegeneRx Biopharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc.
Samjin Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd.
Seikagaku Corporation
Shire Plc
Sucampo Pharmaceuticals, Inc.
TearSolutions, LLC.
Xigen SA
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Keratoconjunctivitis sicca (Dry Eye) Overview 9
Therapeutics Development 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 11
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 19
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 23
AB2 Bio Ltd. 23
Akari Therapeutics, Plc 24
Allergan Plc 25
Circadian Technologies Limited 26
Delenex Therapeutics AG 27
Digna Biotech, S.L. 28
Dompe Farmaceutici S.p.A. 29
HanAll Biopharma Co., Ltd. 30
Herantis Pharma Plc 31
Huons Co., Ltd. 32
InSite Vision Incorporated 33
Kala Pharmaceuticals, Inc. 34
Kissei Pharmaceutical Co., Ltd. 35
Kukje Pharmaceutical Industry Co., Ltd. 36
Laboratorios Sophia S.A. de C.V. 37
Lee's Pharmaceutical Holdings Limited 38
Lipicard Technologies Limited 39
Merck & Co., Inc. 40
Mimetogen Pharmaceuticals Inc. 41
Mitotech S.A. 42
Nanomerics Ltd 43
Neuroptis Biotech 44
Novaliq GmbH 45
Ocular Therapeutix, Inc. 46
Oculis ehf 47
OncoNOx ApS 48
Otsuka Holdings Co., Ltd. 49
Parion Sciences, Inc. 50
PharmaReaserch Products Co., Ltd. 51
RegeneRx Biopharmaceuticals, Inc. 52
Rigel Pharmaceuticals, Inc. 53
Samjin Pharmaceutical Co., Ltd. 54
Santen Pharmaceutical Co., Ltd. 55
Seikagaku Corporation 56
Shire Plc 57
Sucampo Pharmaceuticals, Inc. 58
TearSolutions, LLC. 59
Xigen SA 60
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Target 62
Assessment by Mechanism of Action 65
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
AGN-223575 - Drug Profile 72
AGN-232411 - Drug Profile 73
AVX-012 - Drug Profile 74
Ax-8 - Drug Profile 75
BRM-421 - Drug Profile 76
cinhyaluronate sodium - Drug Profile 77
Cis-Urocanic Acid - Drug Profile 78
Cryosim-3 - Drug Profile 81
cyclosporine - Drug Profile 82
cyclosporine - Drug Profile 83
cyclosporine - Drug Profile 86
cyclosporine - Drug Profile 87
cyclosporine - Drug Profile 88
cyclosporine - Drug Profile 89
cyclosporine - Drug Profile 90
dexamethasone acetate SR - Drug Profile 91
diclofenac sodium - Drug Profile 92
diquafosol tetrasodium - Drug Profile 93
disitertide - Drug Profile 95
DLX-105 - Drug Profile 98
DMT-220 - Drug Profile 100
HL-036 - Drug Profile 101
HU-007 - Drug Profile 102
ISV-101 - Drug Profile 103
KeraKlear - Drug Profile 104
KJ-14003 - Drug Profile 105
KL-7016 - Drug Profile 106
KPI-190 - Drug Profile 107
Lacripep - Drug Profile 108
lifitegrast - Drug Profile 109
LME-636 - Drug Profile 112
loteprednol etabonate - Drug Profile 113
NOP-3 - Drug Profile 115
NOP-5 - Drug Profile 116
Nov-03 - Drug Profile 117
OC-301 - Drug Profile 118
OPX-1 - Drug Profile 119
OX-1001 - Drug Profile 120
ozagrel - Drug Profile 121
P-321 - Drug Profile 122
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 123
PPL-003 - Drug Profile 125
PRD-005 - Drug Profile 127
PRO-148 - Drug Profile 128
Qi-204 - Drug Profile 129
R-348 - Drug Profile 130
rebamipide - Drug Profile 131
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 133
RGN-259 - Drug Profile 135
RP-101 - Drug Profile 137
RU-101 - Drug Profile 138
SA-001 - Drug Profile 139
tadekinig alfa - Drug Profile 140
tavilermide hydrochloride - Drug Profile 141
VGX-100 - Drug Profile 142
XG-104 - Drug Profile 145
ZK-003 - Drug Profile 146
zucapsaicin - Drug Profile 147
Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates 149
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 177
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 182
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 183
Featured News & Press Releases 183
Appendix 188
Methodology 188
Coverage 188
Secondary Research 188
Primary Research 188
Expert Panel Validation 188
Contact Us 188
Disclaimer 189
List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016 14
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Development, H1 2016 21
Comparative Analysis by Unknown Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Development by Companies, H1 2016 (Contd..3) 26
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H1 2016 27
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Akari Therapeutics, Plc, H1 2016 28
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2016 29
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H1 2016 30
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Delenex Therapeutics AG, H1 2016 31
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H1 2016 32
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 33
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 34
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H1 2016 35
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H1 2016 36
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H1 2016 37
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 38
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 39
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016 40
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2016 41
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 42
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H1 2016 43
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H1 2016 44
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2016 45
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H1 2016 46
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H1 2016 47
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H1 2016 48
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2016 49
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H1 2016 50
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H1 2016 51
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H1 2016 52
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 53
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H1 2016 54
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by PharmaReaserch Products Co., Ltd., H1 2016 55
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 56
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 57
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H1 2016 58
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 59
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H1 2016 60
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2016 61
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 62
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H1 2016 63
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H1 2016 64
Assessment by Monotherapy Products, H1 2016 65
Number of Products by Stage and Target, H1 2016 67
Number of Products by Stage and Mechanism of Action, H1 2016 70
Number of Products by Stage and Route of Administration, H1 2016 73
Number of Products by Stage and Molecule Type, H1 2016 75
Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H1 2016 153
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2016 181
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H1 2016 182
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H1 2016 183
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H1 2016 184
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H1 2016 185
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H1 2016 186
List of Figures
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Products, H1 2016 21
Assessment by Monotherapy Products, H1 2016 65
Number of Products by Top 10 Targets, H1 2016 66
Number of Products by Stage and Top 10 Targets, H1 2016 66
Number of Products by Top 10 Mechanism of Actions, H1 2016 69
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 69
Number of Products by Top 10 Routes of Administration, H1 2016 72
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 72
Number of Products by Top 10 Molecule Types, H1 2016 74
Number of Products by Stage and Top 10 Molecule Types, H1 2016 74
